Edith Mitchell
#83,138
Most Influential Person Now
American oncologist and USAF officer
Edith Mitchell's AcademicInfluence.com Rankings
Edith Mitchellphilosophy Degrees
Philosophy
#10046
World Rank
#13728
Historical Rank
#1822
USA Rank
Logic
#7518
World Rank
#9302
Historical Rank
#1149
USA Rank
Download Badge
Philosophy
Why Is Edith Mitchell Influential?
(Suggest an Edit or Addition)According to Wikipedia, Edith Peterson Mitchell is a retired Brigadier general of the United States Air Force and an oncologist. She is clinical professor of medicine and medical oncology at Thomas Jefferson University. In 2015, she became the president of the National Medical Association.
Edith Mitchell's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. (2007) (2262)
- Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. (2008) (1677)
- A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. (2009) (828)
- Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. (2007) (814)
- Recommended guidelines for the treatment of cancer treatment-induced diarrhea. (2004) (546)
- Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patients (2007) (499)
- Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. (2009) (479)
- Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. (2010) (427)
- Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials (2004) (399)
- Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. (2009) (399)
- Carcinoembryonic Antigen in the Staging and Follow-up of Patients with Colorectal Cancer (2005) (362)
- High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 (2005) (347)
- Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. (2006) (247)
- Phase I Evaluation of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer (2012) (224)
- Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. (1986) (192)
- Gastrointestinal toxicity of chemotherapeutic agents. (2006) (174)
- Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. (2008) (169)
- Recommended guidelines for the treatment of chemotherapy-induced diarrhea. (1998) (157)
- Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers (2010) (134)
- Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). (2006) (133)
- Radiolabeled Antibody Imaging in the Management of Colorectal Cancer Results of a Multicenter Clinical Study (1991) (128)
- Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). (1999) (128)
- Irinotecan in the treatment of colorectal cancer. (2006) (126)
- Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. (2013) (123)
- Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT. (1992) (114)
- Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) (2020) (108)
- Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. (2006) (105)
- Lack of Correlation between Epidermal Growth Factor Receptor Status and Response to Panitumumab Monotherapy in Metastatic Colorectal Cancer (2010) (104)
- The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design (2020) (103)
- Immunoscintigraphy of prostatic cancer: Preliminary results with 111in‐labeled monoclonal antibody 7E11‐C5.3 (CYT‐356) (1991) (96)
- Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer (2014) (95)
- Management of cancer treatment-related diarrhea. Issues and therapeutic strategies. (2000) (91)
- Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. (2003) (78)
- Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. (2019) (75)
- Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: A single-institution compilation compared with the National Cancer Institute SEER database (2005) (74)
- Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. (2012) (73)
- Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H. (2020) (68)
- Scintigraphic imaging of body neuroendocrine tumors. (2007) (68)
- A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer. (2013) (64)
- Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). (2017) (64)
- Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. (2009) (63)
- Comparing safety and efficacy of first‐line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer (2009) (62)
- Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1-9%) or negative (<1%) levels of epidermal growth factor receptor (EGFr). (2006) (60)
- A Phase II Trial of Perifosine in Locally Advanced, Unresectable, or Metastatic Pancreatic Adenocarcinoma (2007) (59)
- Higher incidence of aggressive breast cancers in African-American women: a review. (2008) (56)
- Genetic Testing for Inherited Breast Cancer Risk in African Americans (2005) (56)
- Ocular Surface, Ocular Adnexal, and Lacrimal Complications Associated With the Use of Systemic 5-Fluorouracil (2003) (56)
- Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. (2019) (55)
- A randomized trial of first-line irinotecan/fluoropymidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C). (2006) (55)
- Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. (2020) (54)
- Clinical presentation and pathophysiology of EGFRI dermatologic toxicities. (2007) (53)
- Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review (2017) (52)
- Impact of ethnicity on the outcome of men with metastatic, hormone‐sensitive prostate cancer (2017) (52)
- Monoclonal antibodies and radioimmunoconjugates in the diagnosis and treatment of prostate cancer. (1992) (51)
- Cetuximab plus FOLFOX for colorectal cancer (EXPLORE): Preliminary safety analysis of a randomized phase III trial. (2004) (48)
- Panitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor receptor (EGFr) levels: An updated analysis (2007) (48)
- Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer. (2013) (47)
- A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Primary and biomarker analyses. (2011) (39)
- MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer (2018) (38)
- Do elderly patients experience increased perioperative or postoperative morbidity or mortality when given neoadjuvant chemoradiation before esophagectomy? (2011) (37)
- Targeted therapy for metastatic colorectal cancer: role of aflibercept. (2013) (37)
- The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. (2011) (37)
- Gastrointestinal toxicity of chemotherapeutic agents. (1992) (35)
- Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. (2013) (34)
- Results from molecular analysis for therapy choice (MATCH) arm I: Taselisib for PIK3CA-mutated tumors. (2018) (33)
- Sudden-onset thrombocytopenia with oxaliplatin. (2003) (33)
- Updated results of BICC-C study comparing first-line irinotecan/fluoropymidine combinations with or without celecoxib in mCRC: Updated efficacy data (2007) (33)
- Ado-trastuzumab emtansine (T-DM1) in patients with HER2 amplified tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the NCI-MATCH Trial (EAY131) Sub-protocol Q. (2019) (33)
- MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC). (2016) (32)
- Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial. (2020) (31)
- Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer. (2015) (31)
- Molecular analysis for therapy choice (MATCH) arm W: Phase II study of AZD4547 in patients with tumors with aberrations in the FGFR pathway. (2018) (30)
- The Influence of Prognostic Factors and Adjuvant Chemoradiation on Survival After Pancreaticoduodenectomy for Ampullary Carcinoma (2011) (30)
- Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism (2015) (29)
- How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials (2017) (29)
- Role of carcinoembryonic antigen in the management of advanced colorectal cancer. (1998) (28)
- Clinical management of EGFRI dermatologic toxicities: US perspective. (2007) (27)
- Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction. (2000) (27)
- Determinants of pain severity changes in ambulatory patients with cancer: an analysis from Eastern Cooperative Oncology Group trial E2Z02. (2014) (26)
- Colorectal Cancer Vaccines: Antiidiotypic Antibody, Recombinant Protein, and Viral Vector (2000) (26)
- Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131) (2020) (26)
- Panitumumab monotherapy in patients with metastatic colorectal cancer and cetuximab infusion reactions: a series of four case reports. (2009) (26)
- Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial. (2018) (25)
- Anti-idiotypic antibody and recombinant antigen vaccines in colorectal cancer patients. (2001) (25)
- RTOG 0247: A randomized phase II study of neoadjuvant capecitabine and irinotecan versus capecitabine and oxaliplatin with concurrent radiation therapy for locally advanced rectal cancer (2008) (25)
- Modified nucleosides in human serum. (1992) (24)
- Validation of tumor protein marker quantification by two independent automated immunofluorescence image analysis platforms (2016) (24)
- Final STEPP results of prophylacatic versus reactive skin toxicity (ST) treatment (tx) for panitumumab (pmab)-related ST in patients (pts) with metastatic colorectal cancer (mCRC). (2009) (24)
- Fair, just and compassionate: A pilot for making allocation decisions for patients requesting experimental drugs outside of clinical trials (2018) (23)
- Monoclonal antibodies in gastrointestinal cancers. (1988) (22)
- Abstract B080: Update on the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH/EAY131) precision medicine trial (2018) (21)
- NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) trial: A novel public-private partnership (2016) (20)
- Monoclonal anti-idiotypic antibody mimicking the gastrointestinal carcinoma-associated epitope CO17-1A elicits antigen-specific humoral and cellular immune responses in colorectal cancer patients. (2003) (18)
- Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. (2002) (17)
- Management of hypersplenism by partial splenic embolization with ethylene vinyl alcohol copolymer. (2010) (16)
- Abstract CT101: NCI-molecular analysis for therapy choice (NCI-MATCH) clinical trial: interim analysis (2016) (16)
- A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard). (2012) (16)
- Phase II trial of irinotecan/docetaxel for advanced pancreatic cancer with randomization between irinotecan/docetaxel and irinotecan/docetaxel plus C225, a monoclonal antibody to the epidermal growth factor receptor (EGF-r) : Eastern Cooperative Oncology (2007) (16)
- N9841: A randomized phase III equivalence trial of irinotecan (CPT-11) versus oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) in patients (pts) with advanced colorectal cancer (CRC) previously treated with 5FU (2005) (16)
- A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer. (2013) (16)
- A phase II, open-label trial of skin toxicity (ST) evaluation (STEPP) in metastatic colorectal cancer (mCRC) patients (pts) receiving panitumumab (pmab) + FOLFIRI or irinotecan-only chemotherapy (CT) as 2nd-line treatment (tx): Interim analysis (2008) (15)
- Updated results of STEPP, a phase 2, open-label study of pre-emptive versus reactive skin toxicity treatment in metastatic colorectal cancer (MCRC) patients receiving panitumumab plus folfiri or irinotecan-only chemotherapy as second-line treatment (2008) (15)
- Phase II ECOG trial of irinotecan/docetaxel with or without cetuximab in metastatic pancreatic cancer: Updated survival and CA19–9 results (2008) (15)
- Irinotecan in preoperative combined-modality therapy for locally advanced rectal cancer. (2000) (15)
- 5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study (2015) (14)
- 116MO Efficacy, safety, and quality of life (QoL) with futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements: FOENIX-CCA2 (2020) (14)
- Racial Disparities in Rates of Surgery for Esophageal Cancer: a Study from the National Cancer Database (2020) (14)
- Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors (2021) (14)
- Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling (2018) (13)
- Contributions of nitrosoureas to cancer treatment. (1986) (13)
- Immunoscintigraphy with111 In-satumomab pendetide in patients with colorectal adenocarcinoma: Performance and impact on clinical management (1994) (12)
- Results of 3rd line therapy on N9841: a randomized phase III trial of oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) versus irinotecan (CPT-11) in patients (pts) with advanced colorectal cancer (CRC) previously treated with prior 5FU chemotherapy (2005) (12)
- Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer (2016) (12)
- 54P Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/other rearrangements: Subgroup analyses of a phase II study (FOENIX-CCA2) (2020) (12)
- NCI-MATCH (Molecular Analysis for Therapy Choice) – a national signal finding trial. (2016) (11)
- Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma. (2023) (11)
- Epirubicin in non-oat cell lung cancer--response rates and the importance of immunopathology: a Northern California Oncology Group Study. (1986) (11)
- A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group. (2017) (11)
- Determining efficacy of breast cancer therapy by PET imaging of HER2 mRNA. (2012) (11)
- Safety and efficacy of first-line irinotecan/fluoropymidine combinations in mCRC patients >65 years compared with those ≤65: The BICC-C study (2007) (11)
- Dabrafenib and trametinib in patients with tumors with BRAF V600E/K mutations: Results from the molecular analysis for therapy choice (MATCH) Arm H. (2019) (11)
- NCI-MATCH Arms N & P: Phase II study of PI3K beta inhibitor GSK2636771 in patients (pts) with cancers (ca) with PTEN mutation/deletion (mut/del) or PTEN protein loss. (2018) (10)
- Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204). (2019) (10)
- Anti-idiotypic antibody (Ab2) vaccines: Coupling of Ab2 BR3E4 to KLH increases humoral and/or cellular immune responses in animals and colorectal cancer patients (2001) (10)
- Feasibility and results of a randomized phase Ιb study of fractionated 90Υ-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having two or more prior therapies. (2014) (9)
- Outcomes differences for African Americans and Caucasians treated with bevacizumab, FOLFOX4 or the combination in patients with metastatic colorectal cancer (MCRC): Results from the Eastern Cooperative Oncology Group Study E3200 (2007) (9)
- A randomized, phase IIb study of sunitinib plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) versus bevacizumab plus mFOLFOX6 as first-line treatment for metastatic colorectal cancer (mCRC): Interim results. (2010) (9)
- Randomized phase II trial of preoperative combined modality chemoradiation for distal rectal cancer (2004) (9)
- Abstract CT139: NCI Molecular Analysis for Therapy Choice (NCI-MATCH EAY131) arm B: Phase II study of afatinib in patients (pts) with HER2 (ERBB2) activating mutations (2019) (8)
- Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial (2022) (8)
- A phase II trial of preoperative paclitaxel, carboplatin, 5-FU and radiation in patients with resectable esophageal or gastric cancer (Ca) (2004) (8)
- MAVERICC, a phase II study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC): Outcomes by tumor location and KRAS status. (2016) (7)
- Phase II trial of 4'-epi-doxorubicin in advanced colorectal carcinoma: a Northern California Oncology Group study. (1985) (7)
- Intergroup randomized phase III study of postoperative oxaliplatin, 5-fluorouracil and leucovorin (mFOLFOX6) vs mFOLFOX6 and bevacizumab (Bev) for patients (pts) with stage II/ III rectal cancer receiving pre-operative chemoradiation. (2016) (7)
- Dermatological toxicities of panitumumab in the treatment of patients with metastatic colorectal cancer (mCRC) from three clinical studies (2007) (7)
- Bisphosphonate therapy for women with breast cancer and at high risk for osteoporosis. (2007) (6)
- A randomized, phase I/II trial of AMG 102 or AMG 479 in combination with panitumumab (pmab) compared with pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Safety and efficacy results. (2011) (6)
- Abstract CT138: NCI-MATCH EAY131 -Z1I: Phase II study of AZD1775, a wee-1 kinase inhibitor, in patients with tumors containingBRCA1andBRCA2mutations (2019) (6)
- Impact of Pretreatment Tumor Size and Lymph Nodes on Pathologic Complete Response and Survival in a Prospective Trial of Chemoradiation for Locally Advanced Rectal Cancer (2005) (6)
- E2208: Randomized phase II study of paclitaxel with or without the anti-IGF-IR antibody cixutumumab (IMC-A12) as second-line treatment for patients with metastatic esophageal or GE junction cancer. (2014) (6)
- Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F (2022) (6)
- Panitumumab (pmab) plus AMG 102 in patients (pts) with wild-type KRAS metastatic colorectal cancer (mCRC): Updated safety results. (2010) (6)
- Institutional experiences with panitumumab monotherapy in metastatic colorectal cancer (mCRC) patients (pts) intolerant to cetuximab (2007) (6)
- Results of RTOG-0012 randomized phase II study of neoadjuvant combined modality chemoradiation for distal rectal cancer (2004) (6)
- Phase II studies of methyl glyoxal bis‐guanylhydrazone (NSC 32946) in carcinoma of the colon and lung (1982) (6)
- Correlation of thymidine phosphorylase (TP), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) expression in primary and metastatic sites with response to capecitabine plus irinotecan in patients with colorectal cancer. (2004) (5)
- Prognostic impact of race and ethnicity in the treatment of colorectal cancer. (2005) (5)
- A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group (2017) (5)
- Positive Association of Fibroadenomatoid Change with HER2-Negative Invasive Breast Cancer: A Co-Occurrence Study (2015) (5)
- Oxaliplatin with 5-FU or as a single agent in advanced/metastatic colorectal cancer. (2000) (5)
- Randomized phase III study of 3 irinotecan regimens in 1st-line metastatic colorectal cancer (CRC): safety/tolerability of irinotecan + oral capecitabine with or without celecoxib (BICC) (2005) (5)
- Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208. (2018) (4)
- Malignant cell-specific pro-tumorigenic role of type I interferon receptor in breast cancers (2020) (4)
- Phase II trial of methyl-G (methylglyoxal bis-guanylhydrazone) in patients with metastatic renal cell carcinoma. (1981) (4)
- Does diabetes mellitus influence pathologic complete response and tumor downstaging after neoadjuvant chemoradiation for esophageal and gastroesophageal cancer? A two‐institution report (2010) (4)
- Clinical presentations and outcomes in pulmonary embolism patients with cancer (2020) (4)
- Personalized Nutrition as a Key Contributor to Improving Radiation Response in Breast Cancer (2021) (4)
- Mucinous colloid carcinoma of the colon metastatic to the breast. (2012) (4)
- A phase I/II trial of etoposide and cisplatin in extensive small cell lung cancer: a cancer and leukemia group B study. (1996) (4)
- Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F. (2020) (4)
- Randomized phase II trial of preoperative combined modality chemoradiation for distal rectal cancer. (2004) (4)
- Phase II trial of 4'-epi-doxorubicin in metastatic melanoma. (1984) (4)
- Advancing Inclusive Research: Establishing Collaborative Strategies to Improve Diversity in Clinical Trials. (2022) (3)
- Abstract PO-068: Survey of healthcare providers in the ECOG-ACRIN cancer research group: Attitudes, knowledge, and practice behaviors about LGBTQ patients with cancer (2020) (3)
- The consistency of effect of ziv-aflibercept (Z) in the bevacizumab (B) pre-treated subgroup of patients (pts) in the velour trial stratified by first-line progression ≥ 9 months (mos) versus < 9 mos. (2014) (3)
- E7208: A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus ramucirumab (ICR) in second-line therapy of KRAS wild-type colorectal cancer (CRC). (2014) (3)
- Phase III study of standard triweekly versus dose-dense biweekly capecitabine (C) + oxaliplatin (O) + bevacizumab (B) as first-line treatment for metastatic colorectal cancer (mCRC): XELOX-A-DVS (dense versus standard): Interim analysis. (2016) (3)
- Phase II trial of mitoxantrone in advanced colorectal cancer. (1982) (3)
- Circulating endothelial cells (CEC) and circulating tumor cells (CTC) in patients (pts) with metastatic colorectal cancer (mCRC). (2006) (3)
- Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B. (2022) (3)
- Colorectal cancer in the young (2012) (3)
- Abstract LB-010: Molecular analysis for therapy choice (NCI-MATCH, EAY131) arm Z1B: Phase II trial of palbociclib forCCND1, 2 or 3amplified tumors (2019) (3)
- African American Patients’ Psychosocial Support Needs and Barriers to Treatment: Patient Needs Assessment (2016) (3)
- Colorectal cancer in African American and Caucasian patients: A comparison of an urban, university hospital with the National Cancer Institute SEER database. (2011) (3)
- Safety summary of panitumumab (pmab) in combination with chemotherapy (ctx) from four clinical trials in patients (pts) with metastatic colorectal cancer (mCRC). (2009) (3)
- Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I (2022) (3)
- Abstract PL03-01: NCI-MATCH: A new paradigm in the era of genomic oncology (2018) (3)
- Leadership Diversity and Development in the Nation's Cancer Centers. (2022) (2)
- Colorectal cancer characteristics and outcomes in patients less than age 50: A comparison of an urban university hospital with the NCI SEER database. (2012) (2)
- Combined modality therapy of locally advanced adenocarcinoma of the rectum: Update of a phase I trial of preoperative radiation (RT) with concurrent capecitabine (Cap) and irinotecan (Ir). (2006) (2)
- Neuronatin is a modifier of estrogen receptor-positive breast cancer incidence and outcome (2019) (2)
- Activity of fractionated radioimmunotherapy (RAIT) with 90Y clivatuzumab tetraxetan (90Y-hPAM4) plus gemcitabine (Gem) in advanced pancreatic cancer (APC): Final results from a two-part study. (2012) (2)
- Phase II study of PCNU in colorectal carcinoma. (1981) (2)
- Understanding Modern Medical Centers: Beyond Simone-Intersectional Maxims for a New Era. (2022) (2)
- Gemcitabine, Oxaliplatin and Bevacizumab in patients with biliary tract cancers (2013) (2)
- Ascorbic acid plus gemcitabine (gem) and erlotinib (erl) in patients with metastatic pancreatic cancer (mPanc): Preliminary safety results. (2010) (2)
- Efficacy endpoints of RTOG 0247: A randomized phase II study of neoadjuvant capecitabine (C) and irinotecan (I) or C and oxaliplatin (O) with concurrent radiation therapy (RT) for locally advanced rectal cancer. (2011) (2)
- Abstract 2257: Phase II study of dual immune checkpoint blockade (ICB) with durvalumab (Durva) plus tremelimumab (T) following palliative hypofractionated radiotherapy (SBRT) in patients (pts) with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) progressing on chemotherapy: NSABP FC- (2019) (2)
- American Society of Colon and Rectal Surgeons 91st Annual Convention Podium and Poster abstracts (1992) (2)
- Abnormal hair growth in patients (pts) with metastatic colorectal cancer (mCRC) treated with the anti-epidermal growth factor receptor (EGFr) monoclonal antibody (mAb) panitumumab (Pmab) (2008) (2)
- Breast cancer in low-income countries: India as a model. (2014) (2)
- Response to the combination of cetuximab, bevacizumab and irinotecan (cetux/bev/iri) in patients (pts) previously treated with 3rd-line panitumumab, following disease progression on oxaliplatin, irinotecan and a fluoropyrimidine (2007) (1)
- Establishing a Primary Care Alliance for Conducting Cancer Prevention Clinical Research at Community Sites (2021) (1)
- Gastrointestinal cancer committee (2001) (1)
- Radiation Therapy Oncology Group. Research Plan 2002-2006. Gastrointestinal Cancer Committee. (2001) (1)
- Abstract P5-01-07: Fibroadenomatoid changes are more prevalent in middle-aged women and have a positive association with invasive breast cancer (2012) (1)
- Sexual Health Toxicity in Cancer Survivors: Is There a Gender Disparity in Physician Evaluation and Intervention? (2020) (1)
- P-0119THE CD4/6 INHIBITOR, PD0332991, HAS ACTIVITY IN METASTATIC HEPATOCELLULAR CARCINOMA: PRELIMINARY RESULTS OF A PHASE II TRIAL (2013) (1)
- Prognosis after rectal cancer treatment in blacks and whites: advanced stage at diagnosis or other factors? (2003) (1)
- Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q' (2021) (1)
- Phase II trials of cetuximab plus combined modality therapy (CMT) in squamous cell carcinoma of the anal canal (SCCAC) with and without human immunodeficiency virus (HIV) infection. (2016) (1)
- A phase I open-label, dose-escalation study of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. (2012) (1)
- Consistent Surgeon Evaluations of Three-Dimensional Rendering of PET/CT Scans of the Abdomen of a Patient with a Ductal Pancreatic Mass (2013) (1)
- Prospective validation of genetic predictors of aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) in a racially diverse cohort: Results from ECOG-ACRIN E1Z11. (2021) (1)
- Abstract P3-05-10: Glucocorticoid and aldosterone mimic progestin-induction of a therapy-resistant cytokeratin-5 positive cell population in estrogen receptor-positive breast cancer through a Bcl6-dependent mechanism (2015) (1)
- Medically Underrepresented Populations In National Cancer Institute (NCI) Sponsored Cancer Clinical Trials: Refining the Calculation of Accrual Targets. (2015) (1)
- Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1K (2022) (1)
- Scintigraphic Imaging of Body Neuroendo (2007) (1)
- Colon cancer antigen and anti-idiotype vaccines. (2003) (1)
- Tumor size as a predictor of pathologic complete response (pCR) and survival in a prospective trial of chemoradiation for locally advanced rectal cancer (2005) (1)
- Abstract LBA003: Erdafitinib in patients with tumors harboring FGFR gene mutations or fusions: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol K2 (2021) (1)
- Racial disparity trends in clinical presentation and outcomes in colorectal cancer: Findings from an urban university hospital. (2011) (1)
- High PD-L2 Predicts Early Recurrence of ER-Positive Breast Cancer (2023) (1)
- A phase II study of PD-0332991 in patients with advanced hepatocellular cancer. (2013) (1)
- A phase 2 study of defactinib (VS-6063) in patients with NF2 altered tumors: Results from NCI-match (EAY131) subprotocol U. (2021) (1)
- Phase I trial of thalidomide and capecitabine for treatment of metastatic colorectal cancer. (2005) (1)
- Abstract A079: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH): A successful precision medicine signal-seeking trial in patients (pts) with rare variants and refractory malignancies (2019) (1)
- PRIMARY ANALYSIS AND BIOMARKER EVALUATION: RANDOMIZED PHASE IB/II STUDY OF RILOTUMUMAB (AMG 102) OR GANITUMAB (AMG 479) WITH PANITUMUMAB VERSUS PANITUMUMAB ALONE IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) (2011) (1)
- 553P Activity of trastuzumab and pertuzumab (HP) in patients with non-breast/gastroesophgeal HER2-amplified tumours: Results of the NCI-MATCH trial (EAY131) subprotocol J (2020) (1)
- North American (NA) subgroup results from VELOUR: Ziv-aflibercept versus placebo plus FOLFIRI in mCRC that is resistant to or has progressed after an oxaliplatin-containing regimen. (2013) (1)
- An adaptive randomized phase II trial to determine pathologic complete response with the addition of carboplatin with and without ABT-888 to standard chemotherapy in the neoadjuvant treatment of triple-negative breast cancer. (2013) (1)
- Management of Epidermal Growth Factor Receptor Inhibitor-Induced Dermatologic Toxicity (2010) (1)
- The accuracy of transrectal ultrasound before chemoradiation in predicting survival and after chemoradiation in predicting pathological stage in patients with rectal cancer (2005) (0)
- Modified nucleoside levels in the serum of patients with chronic lymphocytic leukemia (1987) (0)
- Phase II trial of afatinib in patients with EGFR-mutated solid tumors excluding lung cancer: results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A (2022) (0)
- Online Report from ASCO 2010 PRINCIPLES ON THE PATHWAY TO TREATMENT : BIOMARKERS COMPARATIVE EFFECTIVENESS SHARED DECISION MAKING TREATMENT EDUCATIONAL PLANNING COMMITTEE (0)
- PD10-06: Loss of the Retinoblastoma Tumor Suppressor (RB) in Triple Negative Breast Cancer Is Associated with a Favorable Prognosis. (2011) (0)
- Biomarker distribution and characteristics for the first 100 patients in MAVERICC, a randomized phase II study of mFOLFOX6-bevacizumab (BV) versus FOLFIRI-BV in previously untreated metastatic colorectal cancer (mCRC). (2013) (0)
- Final STEPP results of prophylacatic versus reactive skin toxicity (ST) treatment (tx) for panitumumab (pmab)-related ST in patients (pts) with metastatic colorectal cancer (mCRC). (2009) (0)
- Radiation Therapy Compliance/Quality Assurance (QA) in 2 Phase 2 Trials of Cetuximab Plus Combined Modality Therapy (CMT) Including Chemotherapy and Radiation Therapy (RT) for Patients With Squamous Cell Carcinoma of the Anal Canal (SCCAC) (AMC045) (2016) (0)
- Abstract P5-14-03: Breast cancer screening and follow-up of abnormal mammogram results: A population-based study comparing results from an urban university cancer center to a national database. (2012) (0)
- Exploratory RAS analysis of the phase Ib/II 20060447 trial of rilotumumab (R) or ganitumab (G) plus panitumumab (pmab) versus pmab alone in patients (pts) with previously treated metastatic colorectal cancer (mCRC). (2015) (0)
- Abstract C074: Racial disparities in diabetes prevalence in prostate cancer patients on androgen deprivation therapy (2023) (0)
- Abstract B55: Hypoxanthine wobble base multimutant KRAS2 mRNA PET imaging agent in G12D mice (2014) (0)
- Comprehensive genomic profiling in colorectal cancer (CRC) to identify differing frequencies of clinically relevant genomic alterations (CRGA) in tumors of patients (pts) less than age 50 as compared to those of pts over age 65. (2016) (0)
- Abstract 3338: Understanding the effect of racial disparities on patients response to dietary intervention during cancer therapy (2019) (0)
- Production of radiolabeled monoclonal antibody conjugates by photoaffinity labeling (1990) (0)
- EDUCATIONAL PLANNING COMMITTEE (2012) (0)
- American College of Nuclear Medicine (ACNM) 2012 ACNM Annual Meeting and SNMMI Mid-Winter Meeting Resident and Fellow Abstracts (2012) (0)
- Stage of disease and initial surgical intervention in colon cancer patients: An exploratory analysis of the SEER database. (2019) (0)
- 2112 Preoperative paclitaxel, carboplatin, 5-FU and radiation in patients with resectable esophageal or gastric cancer: A phase I study (1999) (0)
- Impact of cancer in pulmonary embolism presentation and outcomes: A large academic center study. (2019) (0)
- A phase II trial of preoperative paclitaxel, carboplatin, 5-FU and radiation in patients with resectable esophageal or gastric cancer (Ca). (2004) (0)
- Abstract P1-08-20: Increased risk of hormone therapy failure in breast cancers expressing low phospho-Stat5: Validation of quantitative immunofluorescence assay parameters (2013) (0)
- Phase II study of sunitinib in tumors with c-KIT mutations: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol V (2022) (0)
- Molecular and Genomic Factors in Colorectal Cancer to Optimize Therapeutic Decisions and Patient Care (2015) (0)
- Abstract A102: The role of socioeconomic status, pathology and genetic biomarkers in explaining racial disparities in breast cancer survival (2010) (0)
- Chapter 6 High Performance Liquid Chromatography of Modified Nucleosides in Human Serum (1990) (0)
- Abstract CT061: Binimetinib in patients with tumors withNRASmutations: NCI-MATCH ECOG-ACRIN Cancer Research Group subprotocol EAY131-Z1A (2020) (0)
- Increased access for and enhancement of cancer (ca) patients (pts) participation (par) in clinical trials (cts) by alleviation of financial toxicity. (2018) (0)
- Assessing Real-World Racial Differences Among Patients With Metastatic Triple-Negative Breast Cancer in US Community Practices (2022) (0)
- 530P Phase II study of PI3K inhibitor copanlisib in cancer patients with deleterious PTEN mutations and retained PTEN protein expression: Results from the NCI-MATCH Trial (EAY131) sub-protocol Z1H (2021) (0)
- PCN19 AGE DISPARITIES IN INFLAMMATORY BREAST CANCER INITIAL SURGICAL RESECTION AND MORTALITY: AN ANALYSIS OF 1991-2015 SEER DATA (2019) (0)
- Value of laparotomy in the staging of Hodgkin's disease. An analysis of 100 consecutive patients. (1982) (0)
- Racial disparities in the presentation of hepatocellular carcinoma in the population 65+ years in the United States. (2018) (0)
- Biomarker analysis by breast cancer phenotype in African-American versus Caucasian patients: Correlates with survival (2007) (0)
- SU-E-T-131: Artificial Neural Networks Applied to Overall Survival Prediction for Patients with Periampullary Carcinoma (2015) (0)
- Recurrence Patterns and Predictors of Recurrence After Neoadjuvant Chemoradiation (CRT) Followed by Surgery for Esophageal Cancer (2012) (0)
- Abstract 2422: Discordant opinions about cancer screening for the LGBTQ+ community (2019) (0)
- Racial disparities in the initial treatment of hepatocellular carcinoma in the population 65+ years in the United States. (2018) (0)
- OF NEOADJUVANT CAPECITABINE AND IRINOTECAN OR CAPECITABINE AND OXALIPLATIN WITH CONCURRENT RADIOTHERAPY FOR PATIENTS WITH LOCALLYADVANCED RECTAL CANCER (2012) (0)
- Longitudinal Quality of Life (QOL) and Patient-Reported Bowel Function in RTOG 0247 (2011) (0)
- Carcinoma of the anal region. (1988) (0)
- Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial. (2023) (0)
- Advances in the treatment of metastatic colorectal cancer. (1998) (0)
- Associations between oncogenic risk markers and clinical outcomes among black and white colorectal cancer patients. (2020) (0)
- 18-FDG PET/CT staging in intraductal breast cancer: Correlation of SUV max with hormone receptor status and HER-2 gene expression (2013) (0)
- Endocrine treatment for metastatic breast cancer. (1985) (0)
- Five-Year Updated Results of RTOG-0012 Randomized Phase II Study of Neoadjuvant Combined Modality Ch (2011) (0)
- A comparison of the WHO 2004 and 2010 classification systems in pancreatic neuroendocrine tumors (PNET). (2014) (0)
- Abstract P4-09-06: High levels of Bruton's tyrosine kinase (BTK) protein is associated with favorable outcome in breast cancer (2018) (0)
- Predicting overall survival for patients with periampullary carcinoma. (2015) (0)
- Gastrointestinal toxicity of chemotherapeutic agents. (2006) (0)
- Abstract A089: Adolescent and young adult (AYA) cohort of the NCI MATCH clinical trial (EAY131) (2019) (0)
- Pancreatic Cancer Updates and Clinical Applications in Patient Care (2019) (0)
- O-0004FRACTIONATED RADIOIMMUNOTHERAPY WITH 90ϒ-CLIVATUZUMAB TETRAXETAN IN PATIENTS WITH METASTATIC PANCREATIC CANCER AFTER ≥ 2 PRIOR THERAPIES (2013) (0)
- Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2. (2023) (0)
- An analysis of the histologic evaluation of lung cancer. (1985) (0)
- Abstract PO-013: Qualitative results to a survey of ECOG-ACRIN members regarding experience with sexual and gender minority patients with cancer (2020) (0)
- SUMMARY AND FUTURE DIRECTIONS FOR INVESTIGATIONS IN COLON AND GASTROESOPHAGEAL CANCERS (2007) (0)
- O-0003 Phase I/II Study of 90Y-Clivatuzumab Tetraxetan (90Y-hPAM4) Combined with Gemcitabine (GEM) in Advanced Pancreatic Cancer (APC) (2012) (0)
- The Compassionate Use Advisory Committee (CompAC) for development of pre-approval access to investigational drugs. (2017) (0)
- P5-14-12: Bayesian Belief Network Mortality Analysis of a Breast Cancer Registry Data Set. (2011) (0)
- Associations between age and stage at presentation among black and white colorectal cancer patients. (2021) (0)
- Intravenous vitamin C in combination with gemcitabine and erlotinib in subjects with metastatic pancreatic cancer. (2011) (0)
- Abstract P2-11-13: High PD-L2 Protein Expression in Cancer Cells is an Independent Marker of Unfavorable Prognosis in Luminal Breast Tumors (2023) (0)
- Abstract B98: Final results of a randomized phase Ib study of fractionated 90Y-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having at least two prior therapies (2015) (0)
- Abstract 2624: Clinical trial participation in real-world patients with metastatic breast cancer: disparities and barriers (2021) (0)
- Gemcitabine, oxaliplatin, and bevacizumab (GEMOX-B): A promising regimen for the treatment of advanced biliary tract cancers. (2011) (0)
- Abstract CT160: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or with Non-V600E, Non-V600K BRAF Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol EAY131-Z1L (2022) (0)
- Clinical Presentation and Outcomes of Patients with Pulmonary Embolism: Does Cancer Matter? (2019) (0)
- Factors Associated with Stage at Presentation Among Patients with Rare Pancreatic Tumors: An Exploratory Analysis of the SEER Database (2019) (0)
- Reply to M. Rother (2010) (0)
- Modern Clinical Outcomes of Periampullary Cancer Following Pancreaticoduodenectomy and Adjuvant Chemoradiation Therapy: A Single-Institution Pancreatic Cancer Registry (2014) (0)
- Long Term Survival after Colonic Stenting and Restenting for Malignant Colonic Obstruction (2010) (0)
- 518 – Racial Disparities in Rates of Surgery for Esophageal Cancer: A Study from the National Cancer Database (2019) (0)
- Abstract PS7-53: Assessing racial differences in patients with metastatic triple-negative breast cancer: Real-world evidence from US community oncology practices (2021) (0)
- Breast cancer in young women: A single center study. (2014) (0)
- Abstract P4-07-52: Caloric Restriction for Oncology Research (CaReFOR): Assessing dietary adherence and outcomes in African American patients during breast cancer treatment (2023) (0)
- Phase I/II study of 90Y-clivatuzumab tetraxetan (90Y-hPAM4) combined with gemcitabine (Gem) in advanced pancreatic cancer (APC): Final results. (2012) (0)
- Histology and stage at presentation among patients with rare pancreatic tumors: An exploratory analysis of the SEER database. (2019) (0)
- Urban/rural disparities in stage at presentation of colorectal cancer among young adults in the United States, 2007-2015. (2019) (0)
- Comprehensive genomic profiling (CGP) defines the genomic landscape of colorectal cancer (CRC) in individuals of African ancestry. (2019) (0)
- Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B (2023) (0)
- Abstract 4253: Pan-cancer analysis of XPO1 R749Q mutations across 217,570 patients reveals association with high tumor mutational burden and therapy resistance (2023) (0)
- Addressing disparities in cancer care and incorporating precision medicine for minority populations. (2023) (0)
- An update to a retrospective comparison of results between the National Breast and Cervical Cancer Early Detection Program and NCI cancer center based early detection program with evidenced based patient navigation and social work support. (2022) (0)
This paper list is powered by the following services:
Other Resources About Edith Mitchell
What Schools Are Affiliated With Edith Mitchell?
Edith Mitchell is affiliated with the following schools:
